Loading…
The use of antidiabetic, antihypertensive, and lipid-lowering medications in the elderly dying with advanced cancer
Background: Maintenance of medications that are unconducive to the quality of life is difficult to justify in dying terminally-ill cancer patients. Objective: We aimed at determining the prevalence of administering antidiabetic, antihypertensive, and lipid-lowering medications to elderly patients dy...
Saved in:
Published in: | Indian journal of palliative care 2019-01, Vol.25 (1), p.124-126 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 126 |
container_issue | 1 |
container_start_page | 124 |
container_title | Indian journal of palliative care |
container_volume | 25 |
creator | Al-Shahri, Mohammad Sroor, Mahmoud Ghareeb, Wael Aboulela, Enas Edesa, Wael |
description | Background: Maintenance of medications that are unconducive to the quality of life is difficult to justify in dying terminally-ill cancer patients. Objective: We aimed at determining the prevalence of administering antidiabetic, antihypertensive, and lipid-lowering medications to elderly patients dying with cancer. Methods: We reviewed the medical records of patients above 60 years of age with advanced cancer who died in a palliative care unit. The collected data included the use of antidiabetic, antihypertensive, and lipid-lowering medications during the last week of life. Results: Of 103 patients, 51.5% were female and the median age was 69 years. The most common cancers included gastrointestinal (40.8%), gynecological (13.6%), and head and neck (12.6%). All patients had advanced cancer and 59.2% had hypertension, 52.4% had diabetes mellitus, and 19.4% had dyslipidemia. During their last week of life, 38.8% received antidiabetic, 23.3% received antihypertensive, and 3.9% received lipid-lowering agents. The data showed that 68.5% of people with diabetes received antidiabetic medications, 37.7% of hypertensive patients received antihypertensive medications, and 20% of dyslipidemics received lipid-lowering agents. Hypoglycemia was reported in 7.5% of patients receiving antidiabetic drugs, while hypotension was reported in 66.7% of patients receiving antihypertensive agents. Conclusion: Many elderly patients dying with advanced cancer in a palliative care unit were maintained on medications for chronic conditions until the very late stages of their lives. For such imminently dying patients, benefits of such medications are unlikely and burdens are possible. Further research is needed to explore physicians' justifications, if any, for maintaining such patients on apparently futile medications. |
doi_str_mv | 10.4103/IJPC.IJPC_96_18 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6388588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A571914207</galeid><sourcerecordid>A571914207</sourcerecordid><originalsourceid>FETCH-LOGICAL-g499b-6aeef80a25798117f42a3b4b05934cf0688fd16b32d176b8e1ed250cfe7e8ce13</originalsourceid><addsrcrecordid>eNptks-PEyEUxydG49bVszcziYnx4FQYmAEuJpvGH2ua6GE9EwbedNilUIeZNv3vZbq72pqGBMLj8748Ht8se43RnGJEPl5__7mYT5MUtcT8STbDQvCCMFI9zWZIMFJgxKqL7EWMtwhRKmrxPLsgiJcIYzrL4k0H-RghD22u_GCNVQ0MVn847Lr9BvoBfLRbmCImd3ZjTeHCDnrrV_kajNVqsMHH3Pp8SGLgDPRun5v9BOzs0OXKbJXXYHI9Lf3L7FmrXIRXD-tl9uvL55vFt2L54-v14mpZrKgQTVErgJYjVVZMcIxZS0tFGtqgShCqW1Rz3hpcN6Q0mNUNBwymrJBugQHXgMll9uledzM2qVANfuiVk5verlW_l0FZeXribSdXYStrwnnFeRJ4_yDQh98jxEGubdTgnPIQxihLzFmFGapYQt_-h96GsffpeYliFFeE4SNqpRxI69uQ7tWTqLyqGBaYlmiiijPUCjykIoOH1qbwCT8_w6dhYG312YR3RwkdKDd0Mbjx8I-n4JvjDv5t3aN_ErC8B3bBDdDHOzcmZ8jE3vmwkxjJyaby4NB_NpW4pDIZTybjydDKR-ORP0UR4eA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2174153717</pqid></control><display><type>article</type><title>The use of antidiabetic, antihypertensive, and lipid-lowering medications in the elderly dying with advanced cancer</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Al-Shahri, Mohammad ; Sroor, Mahmoud ; Ghareeb, Wael ; Aboulela, Enas ; Edesa, Wael</creator><creatorcontrib>Al-Shahri, Mohammad ; Sroor, Mahmoud ; Ghareeb, Wael ; Aboulela, Enas ; Edesa, Wael</creatorcontrib><description>Background: Maintenance of medications that are unconducive to the quality of life is difficult to justify in dying terminally-ill cancer patients. Objective: We aimed at determining the prevalence of administering antidiabetic, antihypertensive, and lipid-lowering medications to elderly patients dying with cancer. Methods: We reviewed the medical records of patients above 60 years of age with advanced cancer who died in a palliative care unit. The collected data included the use of antidiabetic, antihypertensive, and lipid-lowering medications during the last week of life. Results: Of 103 patients, 51.5% were female and the median age was 69 years. The most common cancers included gastrointestinal (40.8%), gynecological (13.6%), and head and neck (12.6%). All patients had advanced cancer and 59.2% had hypertension, 52.4% had diabetes mellitus, and 19.4% had dyslipidemia. During their last week of life, 38.8% received antidiabetic, 23.3% received antihypertensive, and 3.9% received lipid-lowering agents. The data showed that 68.5% of people with diabetes received antidiabetic medications, 37.7% of hypertensive patients received antihypertensive medications, and 20% of dyslipidemics received lipid-lowering agents. Hypoglycemia was reported in 7.5% of patients receiving antidiabetic drugs, while hypotension was reported in 66.7% of patients receiving antihypertensive agents. Conclusion: Many elderly patients dying with advanced cancer in a palliative care unit were maintained on medications for chronic conditions until the very late stages of their lives. For such imminently dying patients, benefits of such medications are unlikely and burdens are possible. Further research is needed to explore physicians' justifications, if any, for maintaining such patients on apparently futile medications.</description><identifier>ISSN: 0973-1075</identifier><identifier>EISSN: 1998-3735</identifier><identifier>DOI: 10.4103/IJPC.IJPC_96_18</identifier><identifier>PMID: 30820114</identifier><language>eng</language><publisher>United States: Wolters Kluwer India Pvt. Ltd</publisher><subject>Anticholesteremic agents ; Antidiabetics ; Antihypertensive agents ; Antihypertensives ; Antilipemic agents ; Blood pressure ; Cancer ; Cancer patients ; Diabetes ; Dosage and administration ; Drug therapy ; Drugs ; Elderly patients ; Health services ; Hospitals ; Hypertension ; Hypoglycemia ; Hypoglycemic agents ; Lipids ; Medical records ; Methods ; Older people ; Original ; Palliative care ; Patients ; Physicians ; Terminal care</subject><ispartof>Indian journal of palliative care, 2019-01, Vol.25 (1), p.124-126</ispartof><rights>COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd.</rights><rights>2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2019 Indian Journal of Palliative Care 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388588/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2174153717?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,44569,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30820114$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Shahri, Mohammad</creatorcontrib><creatorcontrib>Sroor, Mahmoud</creatorcontrib><creatorcontrib>Ghareeb, Wael</creatorcontrib><creatorcontrib>Aboulela, Enas</creatorcontrib><creatorcontrib>Edesa, Wael</creatorcontrib><title>The use of antidiabetic, antihypertensive, and lipid-lowering medications in the elderly dying with advanced cancer</title><title>Indian journal of palliative care</title><addtitle>Indian J Palliat Care</addtitle><description>Background: Maintenance of medications that are unconducive to the quality of life is difficult to justify in dying terminally-ill cancer patients. Objective: We aimed at determining the prevalence of administering antidiabetic, antihypertensive, and lipid-lowering medications to elderly patients dying with cancer. Methods: We reviewed the medical records of patients above 60 years of age with advanced cancer who died in a palliative care unit. The collected data included the use of antidiabetic, antihypertensive, and lipid-lowering medications during the last week of life. Results: Of 103 patients, 51.5% were female and the median age was 69 years. The most common cancers included gastrointestinal (40.8%), gynecological (13.6%), and head and neck (12.6%). All patients had advanced cancer and 59.2% had hypertension, 52.4% had diabetes mellitus, and 19.4% had dyslipidemia. During their last week of life, 38.8% received antidiabetic, 23.3% received antihypertensive, and 3.9% received lipid-lowering agents. The data showed that 68.5% of people with diabetes received antidiabetic medications, 37.7% of hypertensive patients received antihypertensive medications, and 20% of dyslipidemics received lipid-lowering agents. Hypoglycemia was reported in 7.5% of patients receiving antidiabetic drugs, while hypotension was reported in 66.7% of patients receiving antihypertensive agents. Conclusion: Many elderly patients dying with advanced cancer in a palliative care unit were maintained on medications for chronic conditions until the very late stages of their lives. For such imminently dying patients, benefits of such medications are unlikely and burdens are possible. Further research is needed to explore physicians' justifications, if any, for maintaining such patients on apparently futile medications.</description><subject>Anticholesteremic agents</subject><subject>Antidiabetics</subject><subject>Antihypertensive agents</subject><subject>Antihypertensives</subject><subject>Antilipemic agents</subject><subject>Blood pressure</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Diabetes</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Elderly patients</subject><subject>Health services</subject><subject>Hospitals</subject><subject>Hypertension</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic agents</subject><subject>Lipids</subject><subject>Medical records</subject><subject>Methods</subject><subject>Older people</subject><subject>Original</subject><subject>Palliative care</subject><subject>Patients</subject><subject>Physicians</subject><subject>Terminal care</subject><issn>0973-1075</issn><issn>1998-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptks-PEyEUxydG49bVszcziYnx4FQYmAEuJpvGH2ua6GE9EwbedNilUIeZNv3vZbq72pqGBMLj8748Ht8se43RnGJEPl5__7mYT5MUtcT8STbDQvCCMFI9zWZIMFJgxKqL7EWMtwhRKmrxPLsgiJcIYzrL4k0H-RghD22u_GCNVQ0MVn847Lr9BvoBfLRbmCImd3ZjTeHCDnrrV_kajNVqsMHH3Pp8SGLgDPRun5v9BOzs0OXKbJXXYHI9Lf3L7FmrXIRXD-tl9uvL55vFt2L54-v14mpZrKgQTVErgJYjVVZMcIxZS0tFGtqgShCqW1Rz3hpcN6Q0mNUNBwymrJBugQHXgMll9uledzM2qVANfuiVk5verlW_l0FZeXribSdXYStrwnnFeRJ4_yDQh98jxEGubdTgnPIQxihLzFmFGapYQt_-h96GsffpeYliFFeE4SNqpRxI69uQ7tWTqLyqGBaYlmiiijPUCjykIoOH1qbwCT8_w6dhYG312YR3RwkdKDd0Mbjx8I-n4JvjDv5t3aN_ErC8B3bBDdDHOzcmZ8jE3vmwkxjJyaby4NB_NpW4pDIZTybjydDKR-ORP0UR4eA</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Al-Shahri, Mohammad</creator><creator>Sroor, Mahmoud</creator><creator>Ghareeb, Wael</creator><creator>Aboulela, Enas</creator><creator>Edesa, Wael</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><general>Medknow Publications & Media Pvt Ltd</general><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>The use of antidiabetic, antihypertensive, and lipid-lowering medications in the elderly dying with advanced cancer</title><author>Al-Shahri, Mohammad ; Sroor, Mahmoud ; Ghareeb, Wael ; Aboulela, Enas ; Edesa, Wael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g499b-6aeef80a25798117f42a3b4b05934cf0688fd16b32d176b8e1ed250cfe7e8ce13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anticholesteremic agents</topic><topic>Antidiabetics</topic><topic>Antihypertensive agents</topic><topic>Antihypertensives</topic><topic>Antilipemic agents</topic><topic>Blood pressure</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Diabetes</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Elderly patients</topic><topic>Health services</topic><topic>Hospitals</topic><topic>Hypertension</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic agents</topic><topic>Lipids</topic><topic>Medical records</topic><topic>Methods</topic><topic>Older people</topic><topic>Original</topic><topic>Palliative care</topic><topic>Patients</topic><topic>Physicians</topic><topic>Terminal care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Shahri, Mohammad</creatorcontrib><creatorcontrib>Sroor, Mahmoud</creatorcontrib><creatorcontrib>Ghareeb, Wael</creatorcontrib><creatorcontrib>Aboulela, Enas</creatorcontrib><creatorcontrib>Edesa, Wael</creatorcontrib><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of palliative care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Shahri, Mohammad</au><au>Sroor, Mahmoud</au><au>Ghareeb, Wael</au><au>Aboulela, Enas</au><au>Edesa, Wael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of antidiabetic, antihypertensive, and lipid-lowering medications in the elderly dying with advanced cancer</atitle><jtitle>Indian journal of palliative care</jtitle><addtitle>Indian J Palliat Care</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>25</volume><issue>1</issue><spage>124</spage><epage>126</epage><pages>124-126</pages><issn>0973-1075</issn><eissn>1998-3735</eissn><abstract>Background: Maintenance of medications that are unconducive to the quality of life is difficult to justify in dying terminally-ill cancer patients. Objective: We aimed at determining the prevalence of administering antidiabetic, antihypertensive, and lipid-lowering medications to elderly patients dying with cancer. Methods: We reviewed the medical records of patients above 60 years of age with advanced cancer who died in a palliative care unit. The collected data included the use of antidiabetic, antihypertensive, and lipid-lowering medications during the last week of life. Results: Of 103 patients, 51.5% were female and the median age was 69 years. The most common cancers included gastrointestinal (40.8%), gynecological (13.6%), and head and neck (12.6%). All patients had advanced cancer and 59.2% had hypertension, 52.4% had diabetes mellitus, and 19.4% had dyslipidemia. During their last week of life, 38.8% received antidiabetic, 23.3% received antihypertensive, and 3.9% received lipid-lowering agents. The data showed that 68.5% of people with diabetes received antidiabetic medications, 37.7% of hypertensive patients received antihypertensive medications, and 20% of dyslipidemics received lipid-lowering agents. Hypoglycemia was reported in 7.5% of patients receiving antidiabetic drugs, while hypotension was reported in 66.7% of patients receiving antihypertensive agents. Conclusion: Many elderly patients dying with advanced cancer in a palliative care unit were maintained on medications for chronic conditions until the very late stages of their lives. For such imminently dying patients, benefits of such medications are unlikely and burdens are possible. Further research is needed to explore physicians' justifications, if any, for maintaining such patients on apparently futile medications.</abstract><cop>United States</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>30820114</pmid><doi>10.4103/IJPC.IJPC_96_18</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0973-1075 |
ispartof | Indian journal of palliative care, 2019-01, Vol.25 (1), p.124-126 |
issn | 0973-1075 1998-3735 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6388588 |
source | Publicly Available Content Database; PubMed Central |
subjects | Anticholesteremic agents Antidiabetics Antihypertensive agents Antihypertensives Antilipemic agents Blood pressure Cancer Cancer patients Diabetes Dosage and administration Drug therapy Drugs Elderly patients Health services Hospitals Hypertension Hypoglycemia Hypoglycemic agents Lipids Medical records Methods Older people Original Palliative care Patients Physicians Terminal care |
title | The use of antidiabetic, antihypertensive, and lipid-lowering medications in the elderly dying with advanced cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A39%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20antidiabetic,%20antihypertensive,%20and%20lipid-lowering%20medications%20in%20the%20elderly%20dying%20with%20advanced%20cancer&rft.jtitle=Indian%20journal%20of%20palliative%20care&rft.au=Al-Shahri,%20Mohammad&rft.date=2019-01-01&rft.volume=25&rft.issue=1&rft.spage=124&rft.epage=126&rft.pages=124-126&rft.issn=0973-1075&rft.eissn=1998-3735&rft_id=info:doi/10.4103/IJPC.IJPC_96_18&rft_dat=%3Cgale_pubme%3EA571914207%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g499b-6aeef80a25798117f42a3b4b05934cf0688fd16b32d176b8e1ed250cfe7e8ce13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2174153717&rft_id=info:pmid/30820114&rft_galeid=A571914207&rfr_iscdi=true |